Valneva (NASDAQ:VALN) Shares Gap Down - What's Next?

Shares of Valneva SE (NASDAQ:VALN - Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $7.03, but opened at $6.61. Valneva shares last traded at $6.40, with a volume of 9,012 shares.

Analyst Upgrades and Downgrades

VALN has been the topic of several recent research reports. HC Wainwright reaffirmed a "buy" rating and set a $17.00 target price on shares of Valneva in a report on Tuesday, April 15th. Guggenheim reduced their price target on Valneva from $17.00 to $15.00 and set a "buy" rating on the stock in a research report on Monday, March 24th.

Valneva Trading Down 6.8 %

The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25. The firm's 50 day moving average price is $6.92 and its 200 day moving average price is $5.69. The stock has a market capitalization of $547.82 million, a P/E ratio of -50.38 and a beta of 1.85.

Valneva (NASDAQ:VALN - Get Free Report) last posted its earnings results on Thursday, March 20th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.32). Valneva had a negative return on equity of 3.93% and a negative net margin of 4.35%. The company had revenue of $56.48 million during the quarter, compared to analysts' expectations of $55.64 million. As a group, equities research analysts expect that Valneva SE will post 0.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Valneva

Several hedge funds have recently made changes to their positions in the company. Wells Fargo & Company MN increased its stake in shares of Valneva by 14.3% in the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company's stock worth $1,079,000 after acquiring an additional 30,859 shares in the last quarter. ABC Arbitrage SA bought a new position in shares of Valneva during the fourth quarter valued at approximately $84,000. Finally, GAMMA Investing LLC purchased a new position in shares of Valneva during the first quarter valued at approximately $94,000. 11.39% of the stock is currently owned by institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.